You are here

Chrysalis BioTherapeutics, Inc.

Company Information
Address
2200 Market St Ste 609
Galveston, TX 77550-1532
United States



Information

UEI: XW1VFGGRLDW3

# of Employees: 0


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. TP508: A New Drug for Mitigating Lethals Effects of Radiation Exposure

    Amount: $3,000,000.00

    DESCRIPTIONprovided by applicantWith increasing risk of a nuclear accident or detonationthere is a critical need to develop effective medicinal countermeasures that can be delivered to victims after a ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  2. SBIR Topic 291

    Amount: $1,499,927.00

    Not Available

    SBIRPhase II2013Department of Health and Human Services National Institutes of Health
  3. TP508: A New Drug for Mitigating Lethal Effects of Radiatin Exposure

    Amount: $2,789,079.00

    DESCRIPTION (provided by applicant): With recent radiation release from reactors in Japan and increasing probability of nuclear detonation somewhere in the world, there is a critical need for developm ...

    SBIRPhase II2012Department of Health and Human Services National Institutes of Health
  4. Prevention of Allergic Rhinitis with Topical Immunomodulating Antibodies

    Amount: $300,000.00

    DESCRIPTION (provided by applicant): Up to 30% of the US population are now affected by nasal allergy, resulting in a total (direct and indirect) cost of approximately 14.6 billion per year. Seasonal ...

    STTRPhase I2011Department of Health and Human Services National Institutes of Health
  5. TAS::75 0849::TAS

    Amount: $199,757.00

    Over 60% of cancer patients are treated with radiotherapy, yet radiation-induced normal tissue damage can cause organ dysfunction and morbidity. Radiotherapy of CNS tumors is problematic due to potent ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health
  6. TP508:A New Drug for Mitigating Lethal Effects of Radiation Exposure

    Amount: $297,326.00

    DESCRIPTION (provided by applicant): With increasing risk of nuclear detonation there is a need for effective medicinal counter-measures that can be delivered after exposure to prevent radiation-induc ...

    SBIRPhase I2010Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government